Table 2 Results from frequentist and Bayesian paired-sample t-tests showing patient-control differences in [11C]FLB 457 BPND in thalamus.

From: Thalamic dopamine D2-receptor availability in schizophrenia: a study on antipsychotic-naive patients with first-episode psychosis and a meta-analysis

Region

Mean BPND (SD) controls

Mean BPND (SD) patients

Mean BPND difference (SD) (pat-HC)

Lower–Upper 95% CI

Mean %-difference (pat-HC)

p

BF H1:H0

Cohen’s dz

Whole thalamus

3.66 (0.52)

3.28 (0.79)

−0.38 (0.80)

−0.77 to 0.00

−10

0.03

4.7

0.48

Thalamus-prefrontal Cx

4.22 (0.61)

3.74 (0.88)

−0.48 (0.91)

−0.92 to −0.04

−11

0.02

5.8

0.53

Thalamus-temporal Cx

1.47 (0.44)

1.14 (0.41)

−0.24 (0.82)

−0.64 to 0.16

−22

0.11

1.4

0.29

Thalamus-primary motor Cx

1.58 (0.34)

1.36 (0.53)

−0.22 (0.69)

−0.55 to 0.11

−14

0.09

1.6

0.32

Thalamus-premotor Cx

1.90 (0.39)

1.85 (0.64)

−0.04 (0.73)

−0.40 to 0.31

−3

0.40

0.5

0.06

Thalamus-posterior parietal Cx

1.75 (0.22)

1.73 (0.57)

−0.02 (0.56)

−0.29 to 0.25

−1

0.43

0.5

0.04

  1. For informative and default priors for the Bayes Factor (BF) see methods. All t-tests were one-sided expecting lower levels in patients. BF H1:H0 = support in data in favor of the alternative hypothesis over the null hypothesis as quantified using Bayes Factor.
  2. Cx cortex.
Back to article page